| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02263547 | Teriflunomide Elimination|Healthy Volunteers | Drug: teriflunomide|Drug: Colestipol | Derrick Scott Robertson|Genzyme, a Sanofi Company|University of South Florida | Phase 1 | 2015-01-01 | 2016-09-15 |
| NCT01970410 | Multiple Sclerosis | Drug: teriflunomide | Multiple Sclerosis Center of Northeastern New York|Providence Multiple Sclerosis Center | Phase 4 | 2013-10-01 | 2016-10-24 |
| NCT01895335 | Multiple Sclerosis | Drug: Teriflunomide | Sanofi | Phase 4 | 2013-06-01 | 2016-10-10 |
| NCT02490982 | Relapsing Remitting Multiple Sclerosis | Drug: Teriflunomide | Centre hospitalier de l'Universit de Montral (CHUM)|Genzyme, a Sanofi Company|Montreal Neurological Institute and Hospital | Phase 4 | 2015-07-01 | 2016-01-25 |
| NCT01487096 | Multiple Sclerosis | Drug: Teriflunomide|Drug: Placebo (placebo for teriflunomide) | Sanofi | Phase 2 | 2001-04-01 | 2012-10-03 |
| NCT00134563 | Multiple Sclerosis | Drug: Teriflunomide|Drug: Placebo (for teriflunomide) | Sanofi | Phase 3 | 2004-09-01 | 2013-01-02 |
| NCT00622700 | Multiple Sclerosis | Drug: Teriflunomide|Drug: Placebo | Sanofi | Phase 3 | 2008-02-01 | 2017-01-20 |
| NCT00489489 | Multiple Sclerosis | Drug: Teriflunomide|Drug: Placebo (for Teriflunomide)|Drug: Interferon-尾 | Sanofi | Phase 2 | 2007-05-01 | 2012-11-05 |
| NCT00475865 | Multiple Sclerosis | Drug: Teriflunomide|Drug: Placebo (for teriflunomide)|Drug: Glatiramer Acetate (GA) | Sanofi | Phase 2 | 2007-04-01 | 2012-11-05 |
| NCT02046629 | Multiple Sclerosis | Drug: Teriflunomide HMR1726|Drug: cholestyramine | Sanofi | Phase 1 | 2014-05-01 | 2014-08-20 |
| NCT00751881 | Multiple Sclerosis | Drug: Placebo|Drug: Teriflunomide | Sanofi | Phase 3 | 2008-08-01 | 2016-05-27 |
| NCT01252355 | Multiple Sclerosis Relapse | Drug: Teriflunomide|Drug: Placebo (for teriflunomide)|Drug: Interferon-beta (IFN-beta) | Sanofi | Phase 3 | 2011-01-01 | 2014-05-30 |
| NCT00803049 | Multiple Sclerosis | Drug: Teriflunomide (HMR1726) | Sanofi | Phase 3 | 2006-10-01 | 2016-12-05 |
| NCT02792218 | Relapsing Multiple Sclerosis | Drug: Ofatumumab subcutaneous injection|Drug: Placebo orally matching to teriflunomide|Drug: Teriflunomide orally|Drug: Placebo subcutanous injection matching to ofatumumab | Novartis Pharmaceuticals|Novartis | Phase 3 | 2016-09-19 | 2017-02-22 |
| NCT02792231 | Relapsing Multiple Scelrosis | Drug: Ofatumumab subcutaneous injection|Drug: Placebo orally matching to teriflunomide|Drug: Teriflunomide orally|Drug: Placebo subcutaneous injection matching to ofatumumab | Novartis Pharmaceuticals|Novartis | Phase 3 | 2016-08-26 | 2017-02-06 |
| NCT00883337 | Multiple Sclerosis | Drug: Interferon -1a|Drug: Teriflunomide | Sanofi | Phase 3 | 2009-04-01 | 2016-05-04 |
| NCT01403376 | Multiple Sclerosis | Drug: teriflunomide|Drug: Interferon--1|Biological: Influenza vaccine | Sanofi | Phase 2 | 2011-09-01 | 2016-01-21 |
| NCT00228163 | Multiple Sclerosis | Drug: teriflunomide (HMR1726) | Sanofi | Phase 2 | 2002-01-01 | 2015-03-24 |
| NCT02201108 | Multiple Sclerosis | Drug: Teriflunomide HMR1726|Drug: Placebo | Genzyme, a Sanofi Company|Sanofi | Phase 3 | 2014-07-01 | 2017-03-09 |
| NCT02587195 | Multiple Sclerosis | Drug: Teriflunomide | Centre Hospitalier Universitaire de Nice | Phase 3 | 2015-10-01 | 2015-10-23 |
